<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[Mylan Inc. | Company News & Executive Profiles - MYL | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/mylan+inc..html?i=11]]></link>
	<description><![CDATA[Latest company news & analysis, recent events, stock quotes, earning call transcripts, with profiles and descriptions of top business executives for Mylan Inc.]]></description>
	<s:counts start="0" returned="10" found="18" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Earnings Preview: Mylan]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F169497-earnings-preview-mylan%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Mylan MYL is expected to report Q3 earnings on  Thursday, October 29, before the market open, with a conference call scheduled  for 10 am ET.  Guidance Analysts are looking for EPS of 27c on revenue of $1.23B. The  consensus range is 24c-31c for EPS, and $1.18B-$1.28B...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Wed, 28 Oct 2009 08:39:58 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/theflyonthewall.com.html"><![CDATA[theflyonthewall.com]]></category>
		<category domain="http://resources.bnet.com/topic/mylan+inc..html"><![CDATA[Mylan Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MYL</category>
		<category domain="tickers">MYL</category>
	</item>
	<item>
		<title><![CDATA[Teva?s Copaxone Challenged by Mylan]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F162161-tevas-copaxone-challenged-by-mylan%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Zacks.com submits:   Shares of generic player Teva Pharmaceuticals, Inc. TEVA were down approximately 2% on news regarding the acceptance of an abbreviated new drug application ANDA for its multiple sclerosis drug, Copaxone. The ANDA, filed by generic company Mylan, Inc. MYL was accepted for review on September 14,...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Fri, 18 Sep 2009 01:00:37 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/zacks.com.html"><![CDATA[Zacks.com]]></category>
		<category domain="http://resources.bnet.com/topic/mylan+inc..html"><![CDATA[Mylan Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MYL</category>
		<category domain="tickers">MYL</category>
	</item>
	<item>
		<title><![CDATA[Mylan Inc. Q2 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F152569-mylan-inc-q2-2009-earnings-call-transcript%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Mylan Inc. MYL   Q2 2009 Earnings Call Transcript   July 30, 2009 8:30 am ET]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 30 Jul 2009 11:30:38 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/mylan+inc..html"><![CDATA[Mylan Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MYL</category>
		<category domain="tickers">MYL</category>
	</item>
	<item>
		<title><![CDATA[Mylan Inc. Q2 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-326632.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Thank you. Today&#8217;s question-and-answer session will be conducted electronically. Operator instructions And we will move to Marc Goodman with UBS. Marc Goodman - UBS Yes, good morning everybody. Can you give us a little more on what&#8217;s going on in France? It&#8217;s such an important market for...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 30 Jul 2009 10:30:38 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/france.html"><![CDATA[France]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/ubs+ag.html"><![CDATA[UBS AG]]></category>
		<category domain="http://resources.bnet.com/topic/mylan+inc..html"><![CDATA[Mylan Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/pricing.html"><![CDATA[Pricing]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/marketing+research.html"><![CDATA[Marketing Research]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[Marketing]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MYL</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">UBS</category>
		<category domain="tickers">MYL,UBS</category>
	</item>
	<item>
		<title><![CDATA[Earnings Preview: Mylan]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F152195-earnings-preview-mylan%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Mylan MYL is expected to report Q2 earnings Thursday, July 30 before market open, with a conference call scheduled for 8:30 am ET.  Guidance Analysts are looking for EPS of 30c on revenue of $1.22B. The consensus range is 26c-36c for EPS, and $1.14B-$1.29B for revenue, according to First...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Wed, 29 Jul 2009 09:59:33 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/theflyonthewall.com.html"><![CDATA[theflyonthewall.com]]></category>
		<category domain="http://resources.bnet.com/topic/mylan+inc..html"><![CDATA[Mylan Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MYL</category>
		<category domain="tickers">MYL</category>
	</item>
	<item>
		<title><![CDATA[Mylan Inc. Q1 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-294071.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Thank you. Operator instructions. Our first question is from Randall Stanicky with Goldman Sachs. Randall Stanicky &#8211; Goldman Sachs Great. Thanks for the question. Just a two-part question. First Robert, can you just talk about 2010 outlook, are you still comfortable with that range, and are the...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Fri, 01 May 2009 05:13:17 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/guidance.html"><![CDATA[Guidance]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/mylan+inc..html"><![CDATA[Mylan Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/research+%2526+development.html"><![CDATA[Research & Development]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MYL</category>
		<category domain="tickers">MYL</category>
	</item>
	<item>
		<title><![CDATA[Mylan: Showing Up Doubters]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F122001-mylan-showing-up-doubters%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Alpha TimerAllen Phatimer submits:   Mylan&#8217;s MYL comeback is on track! Mylan reported 4Q earnings late last week and the results were excellent. At a time when most long investment theses are deteriorating, this one is intact if not strengthened. EPS of $0.26 came on better than expected revenues,...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Mon, 23 Feb 2009 01:36:17 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/allen+phatimer.html"><![CDATA[Allen Phatimer]]></category>
		<category domain="http://resources.bnet.com/topic/mylan+inc..html"><![CDATA[Mylan Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MYL</category>
		<category domain="tickers">MYL</category>
	</item>
	<item>
		<title><![CDATA[Watson Pharmaceuticals: A Potent Drug Combination]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F113459-watson-pharmaceuticals-a-potent-drug-combination%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Paul Price submits: Watson WPI develops,  manufactures and markets both generic and branded drugs. It also holds a 50%  interest in Somerset Pharmaceuticals a joint venture with Mylan Labs MYL. It  previously had acquired Andrx Group in November 2006, bringing its stable of  marketed products to...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 06 Jan 2009 06:28:57 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/paul+price.html"><![CDATA[Paul Price]]></category>
		<category domain="http://resources.bnet.com/topic/mylan+inc..html"><![CDATA[Mylan Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/watson+pharmaceuticals+inc..html"><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MYL</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">WPI</category>
		<category domain="tickers">MYL,WPI</category>
	</item>
	<item>
		<title><![CDATA[Federal Circuit Affirms Fee Award to Takeda]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F109997-federal-circuit-affirms-fee-award-to-takeda%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Aaron F. Barkoff submits:  Takeda v. Mylan and Alphapharm, Nos. 2007-1269, -1270 (Fed. Cir. 2008)   In an opinion released Monday, the Federal Circuit affirmed a district court decision granting $16.8 million for attorney fees, expenses and expert fees to Takeda (TKPHF.PK) for baseless paragraph IV certification letters...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 09 Dec 2008 10:50:26 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/aaron+f.+barkoff.html"><![CDATA[Aaron F. Barkoff]]></category>
		<category domain="http://resources.bnet.com/topic/mylan+inc..html"><![CDATA[Mylan Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MYL</category>
		<category domain="tickers">MYL</category>
	</item>
	<item>
		<title><![CDATA[Will Mylan Benefit from Healthcare Reforms?]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F109766-will-mylan-benefit-from-healthcare-reforms%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Vahan Janjigian Forbes submits:  Mylan MYL is a leading provider of generic pharmaceuticals. The company more than doubled its revenue base when it acquired Germany-based Merck MRK KGaA&#8217;s generic pharmaceutical business in 2007. This acquisition significantly expanded MYL&#8217;s presence in Europe where it generated 35% of generic sales through...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Mon, 08 Dec 2008 11:13:18 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/vahan+janjigian.html"><![CDATA[Vahan Janjigian]]></category>
		<category domain="http://resources.bnet.com/topic/mylan+inc..html"><![CDATA[Mylan Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MYL</category>
		<category domain="tickers">MYL</category>
	</item>
</channel>
</rss>
